INTERLINK COE Networks & Programs

Join us for the INTERLINK Premier Medical Round Table, a unique event led by INTERLINK's Medical Director, Dr. Richard Freeman. Discover the intricacies behind "Organ Allocation and Preservation: The Hidden Process that Drives the Entire Transplant Industry." While the life-saving potential of transplants is widely recognized, the hidden logistics that bring organs to patients in need are often overlooked. From acquisition and preservation to allocation, it’s a collaborative, evolving process shaped by organizations like UNOS, OPTN, and OPO. Event Details: Date: November 14th, 2024 Time: 9:00 - 10:00 am PST Contact your account manager at Accountmanagers@interlinkhealth.com for your chance to join this session! Don’t miss this opportunity to deepen your knowledge of transplant processes and gain insights into the latest advancements in organ preservation and allocation. #TransplantInnovation #OrganPreservation #MedicalAdvancements #INTERLINK #PremierMedicalRoundTable

INTERLINK is excited to welcome back Julie Doran, RHU, REBC. In her previous role as Senior Sales Director, Julie played a pivotal role in expanding into new verticals and maintaining key client relationships. Now, she returns to join INTERLINK’s Symphony Benefit Solutions team focused on integrating cell/gene therapy, transplant, Dialysis/ESRD, and cancer programs into one cohesive package for Payers, TPAs, and self-funded employers.  #INTERLINK #SymphonyBenefitsSolution #NewTeamAnnouncement

JOIN US FOR AN EDUCATIONAL MEDICAL ROUND TABLE! October 22nd, 2024 from 12:30 pm-1:30 pm PST INTERLINK is pleased to welcome Dr. Jay Fishman from Massachusetts General Hospital. Dr. Fishman will present on xenotransplantation, a revolutionary area of medicine that is advancing from theoretical concept to practical application. Envision a future devoid of organ waitlists, where prevalent conditions such as chronic kidney disease (CKD) and congenital heart disease (CHD) can be addressed proactively. We invite you to join Dr. Fishman as he explores the latest advancements in xenotransplantation and discusses the potential integration of these innovations into our current healthcare practices. Click here to register: https://lnkd.in/ghCjxMME

Join us at Booth #818 to explore how our cutting-edge Gene and Cell Therapy solutions are now integrated with our proven CancerCARE and Transplant programs. We’re focused on improving health outcomes and lowering costs for populations everywhere. Don’t miss the chance to discover how our innovative solutions can benefit your organization. See you at the SIIA National Conference! #SIIA2024 #HealthcareInnovation #GeneTherapy #CancerCare #Transplant #PopulationHealth #CostSavings #HealthCareSolutions

We are excited to announce that the INTERLINK, Symphony, and CancerCARE teams will be attending MCRA this month! Reach out to us to set up a time to chat at the conference, and keep an eye out for Dennis J. Carlson, MBA, Kris Atkins, Julaine Novak, Dana Lamb, and Heidi Scarbrough on September 16-18th! We look forward to seeing you there! #INTERLINK #SymphonyBenefitsSolution #MCRA #CancerCARE

Exciting News! INTERLINK is thrilled to announce that we’ll be attending the SIIA 2024 National LEAD Convention from September 22nd to 24th! We can’t wait to connect with industry leaders and discuss our latest innovation—Symphony Benefits Solution. This inclusive bundle offers comprehensive solutions, including Cancercare, Transplant, ESRD, and cutting-edge gene and cell therapies, tailored to meet your organization's diverse needs. Don’t miss the chance to stop by our new booth #818. We look forward to seeing you there and exploring how Symphony can make a difference in your benefits strategy! #SIIA2024 #HealthcareInnovation #SymphonyBenefits #INTERLINK

Exciting News in Immunotherapy! The FDA has just approved Lymphir™ by Citius Pharmaceuticals.  LYMPHIRTM (Denileukin Diftitox-cxdl, E7777), is a purified reformulation of denileukin diftitox, a previously FDA-approved cancer immunotherapy for the treatment of persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma. Improvements to the original formulation resulted in a therapy that maintains the same amino acid sequence but features greater purity and bioactivity and has been approved for use with relapsed or refractory cutaneous T-cell lymphoma (R/R CTCL). The approval is based on a robust multicenter study, showing a 36.2% overall response rate with significant skin disease reduction. LYMPHIR is the only CTCL therapy that targets the IL-2 receptor, and it’s expected to be available within the next five months. Citius plans to further explore the potential of LYMPHIRTM to treat larger patient populations with additional indications in peripheral T-cell lymphoma (PTCL) and immuno-oncology. LYMPHIRTM has been granted orphan drug designation (ODD) by the FDA for the treatment of CTCL and PTCL   At Symphony Benefits Solution, we are committed to helping your organization navigate the complexities and costs of innovative treatments like this. Reach out to us at Sales@thesymphonyprogram to learn how we can support your gene and cell therapy strategies.

Join us on August 22nd, 2024, from 8:30 - 9:30 am PT for an insightful and exclusive Premier Medical Round Table sponsored by INTERLINK and The Symphony Program, entitled "From Science to Solutions: Gene and Cell Therapy in Today’s Healthcare Landscape." Led by Dr. Carolina Escobar, Symphony's Medical Director of Gene and Cell Therapy, and Kris Atkins, RN, CCM, Executive Vice President, Strategy & Innovation The field of Gene and Cell Therapy is evolving rapidly, with new treatments and innovative applications creating complexities for risk-bearing entities. We will discuss recent and upcoming therapy approvals in this dynamic space. Learn from experts about how these therapies will impact patient populations, understand the pricing mechanisms driving increasing costs, and discover strategies to manage expenses while maintaining access for eligible members. Reach out to your account managers today at Accountmanagers@interlinkhealth.com to discover how you can become eligible to join this premier learning event! Don't miss this opportunity to deepen your understanding and contribute to the advancement of Gene and Cell Therapy! #GeneTherapy #CellTherapy #MedicalInnovation #INTERLINK #PremierMedicalRoundTable

At CancerCARE for Life, we're focused on innovation by developing a new solution to support policyholders in implementing cancer prevention strategies and navigating the complexities of a cancer diagnosis. Message me if you have any questions. #CancerPrevention #HealthcareInnovation Heidi Scarbrough Julaine Novak

INTERLINK is thrilled to be attending the Health Care Administrators Association (HCAA) TPA Summit from July 15-17! We look forward to reconnecting with our current TPA partners in person AND meeting new ones. Hope to see you there! #INTERLINK #TPASUMMIT #HCAA